InMode Ltd. (INMD) AI Stock Analysis

Headquartered in Yokneam, Israel, InMode Ltd. develops, manufactures, and markets minimally invasive aesthetic medical technologies. The company specializes in proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. Its systems enable procedures such as simultaneous liposuction and skin tightening, body and facial contouring, and ablative skin rejuvenation. InMode also provides solutions for women's health conditions, non-invasive products for wrinkle reduction and hair reduction, and hands-free medical aesthetic devices for skin tightening, fat reduction, and muscle stimulation.

InMode expanded annual revenue from $357.6M in FY2021 to a peak of $492.0M in FY2023, reflecting a 5-year revenue CAGR of 12.4% through FY2025. However, revenue fell 19.8% in FY2024 to $394.8M and decreased another 6.2% in FY2025 to $370.5M. Gross margin softened from 85.0% in FY2021 to 78.5% in FY2025, while operating margin dropped from 46.8% to 23.0% over the same span. Net income declined from $197.9M in FY2023 to $93.8M in FY2025, bringing EPS down to $1.58. Over the trailing twelve months ending June 30, 2026, revenue was $374.6M, with quarterly earnings falling 31.0% year-over-year.

As of June 30, 2026, InMode maintained a debt-free profile relative to its reserves, with $501.1M in cash and short-term investments against $4.5M in total debt, yielding net cash of $496.7M. Total assets stood at $720.3M and shareholders' equity reached $629.1M, supporting a current ratio of 8.18 and a debt-to-equity ratio of 0.01. Free cash flow totaled $84.3M in FY2025, while capital expenditures were $972,000. InMode allocated $127.4M to share buybacks in FY2025, helping drive a 31.3% reduction in share count over 5 years.

At a share price of $14.16, InMode has a market capitalization of $814.8M and an enterprise value of $319.9M. The stock trades at a trailing P/E of 11.7x and a forward P/E of 10.0x, both well below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value to EBITDA ratio of 4.6x is also lower than the peer median of 12.0x. Over the past year, INMD shares declined 7.0%, lagging the S&P 500 return of 16.8%, and the stock is down 83.0% over the past 5 years compared to an 83.0% gain for the benchmark.

Wall Street consensus reflects caution, with all 5 analysts tracking InMode issuing a Hold rating. The mean price target is $16.17, implying a 14.2% upside from the last close of $14.16. For the fiscal year ending December 31, 2026, analysts anticipate revenue of $370.3M and an EPS of $1.30, representing a 19.0% decline in earnings. Looking ahead to next fiscal year, 5 analysts project revenue to rise 2.3% to $378.8M with EPS reaching $1.37. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of InMode Ltd. (INMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INMD income statement, INMD balance sheet, INMD key metrics, INMD analyst forecast, INMD chart. See the INMD stock overview for the latest quote and news.